Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micro-bupe: Buprenorphine Microdose Inductions During Hospitalization
NCT05118204Phase 4Terminated
- Sponsor
- Montefiore Medical Center
- Start
- Sep 2022
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) and chronic pain (2 arms), sponsored by Montefiore Medical Center. Primary endpoint: Buprenorphine Treatment Uptake at 7 days. Started Sep 2022; status: terminated.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)chronic pain
Beyond the preview
Go deeper on NCT05118204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118204.